Comparative Pharmacology
Head-to-head clinical analysis: FLEXICORT versus UTICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLEXICORT versus UTICORT.
FLEXICORT vs UTICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLEXICORT contains the active ingredient prednisolone, a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression, inhibition of phospholipase A2, and suppression of inflammatory mediators such as prostaglandins and leukotrienes.
Uticort (betamethasone) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Flexicort is not a recognized drug name in authoritative pharmacological databases. Please verify the correct generic name. Assuming hydrocortisone: Typical adult dose is 10-40 mg orally daily in divided doses or as a single morning dose. Route: oral. Frequency: once or twice daily.
Topical: Apply a thin film to affected area twice daily. Maximum 50 g per week. For short-term use only (≤2 weeks).
None Documented
None Documented
8–12 hours; clinical context: once-daily dosing maintains therapeutic levels, with steady-state achieved within 2–3 days.
Terminal elimination half-life: 2-4 hours in healthy adults; prolonged to 6-12 hours in hepatic impairment.
Renal excretion of inactive metabolites accounts for 95% of elimination; biliary/fecal excretion is minimal at 5%.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% via enterohepatic circulation.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid